Evidence map›Paper›PMID 38565604›Full record

ArticleScientific reports2024

Effect of CHST11, a novel biomarker, on the biological functionalities of clear cell renal cell carcinoma.

Weijing Hu, Yongquan Chen, Lin Zhang, Xiaoling Guo, Xin Wei, Yuan Shao, Dongwen Wang, Bo Wu

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Weijing HuDepartment of Urology, First Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi, China.
Yongquan ChenDepartment of Urology, Shanxi Coal Center Hospital, Taiyuan, 030001, Shanxi, China.
Lin ZhangShanxi Medical University, Taiyuan, 030001, Shanxi, China.
Xiaoling GuoGeriatrics Department, Xi'an Central Hospital, Xi'an, 710003, China.
Xin WeiShanxi Medical University, Taiyuan, 030001, Shanxi, China.
Yuan ShaoDepartment of Urology, The Second Hospital of Tianjin Medical University, Tianjin, 300070, China.
Dongwen WangNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, Guangdong, China.
Bo WuDepartment of Urology, First Hospital of Shanxi Medical University, Taiyuan, 030001, Shanxi, China. 13803466385@163.com.
Shanxi Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Hospital of Shanxi Medical University · CNFirst Hospital of Xi'an · CNSecond Hospital of Tianjin Medical University · CNShanxi Cardiovascular Hospital · CN

Funding

the Beijing Bethune Charitable Foundation, Special Research Fund for Urological Oncology mnzl202029the Research Project Supported by Shanxi Scholarship Council of China 2021-160
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is a common malignant tumor, and the role of carbohydrate sulfotransferase 11 (CHST11) in this cancer remains unclear. Here, by using bioinformatics methods, we comprehensively analyzed the relationship between CHST11 and clinical significance, immune infiltration, functional enrichment, m

Indexed as

CarcinomaCarcinoma, Renal CellKidney NeoplasmsBiomarkersHumansPrognosisSulfotransferasesTumor MicroenvironmentBiomarkersCHST11 protein, humanSulfotransferasesBiomarkerCarbohydrate sulfotransferase 11Clear cell renal cell carcinomaInvasionMigrationProliferationTumor microenvironment

Identifiers

PMID38565604
PMCPMC10987617
OpenAlexW4393442734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.